MBTPS1 and multiple sclerosis: Given that the S1PR-agonist Fingolimod is successfully used to inhibit lymphocyte trafficking in multiple sclerosis (56), studies of S1P subtypes, its receptors and other chemotactic molecules in OSA could open up for new therapy targets in this disease.